ES2139083T3 - Composiciones de vacuna. - Google Patents

Composiciones de vacuna.

Info

Publication number
ES2139083T3
ES2139083T3 ES94921761T ES94921761T ES2139083T3 ES 2139083 T3 ES2139083 T3 ES 2139083T3 ES 94921761 T ES94921761 T ES 94921761T ES 94921761 T ES94921761 T ES 94921761T ES 2139083 T3 ES2139083 T3 ES 2139083T3
Authority
ES
Spain
Prior art keywords
vaccine
vaccine compositions
composition
hepatitis
mucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94921761T
Other languages
English (en)
Inventor
Steven Neville Chatfield
Mark Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medeva Holdings BV
Original Assignee
Medeva Holdings BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings BV filed Critical Medeva Holdings BV
Application granted granted Critical
Publication of ES2139083T3 publication Critical patent/ES2139083T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION SUMINISTRA EL USO DE UN CAPSIDO DEL VIRUS DE LA HEPATITIS A, O UN FRAGMENTO MUCOSALMENTE INMUNOGENICO O UN EPITOPO DEL MISMO, PARA LA MANUFACTURA DE UNA COMPOSICION DE VACUNA MUCOSAL PARA SU ADMINISTRACION A UNA SUPERFICIE MUCOSAL DE UN PACIENTE PARA INDUCIR LA PRODUCCION DE ANTICUERPO DE LA INMUNOGLOBULINA G DEL SUERO CONTRA LA HEPATITIS A. PREFERIBLEMENTE LA COMPOSICION DE VACUNA SE ADMINISTRA MEDIANTE GUIA INTRANASAL.
ES94921761T 1993-08-12 1994-07-29 Composiciones de vacuna. Expired - Lifetime ES2139083T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939316745A GB9316745D0 (en) 1993-08-12 1993-08-12 Vaccine compositions

Publications (1)

Publication Number Publication Date
ES2139083T3 true ES2139083T3 (es) 2000-02-01

Family

ID=10740372

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94921761T Expired - Lifetime ES2139083T3 (es) 1993-08-12 1994-07-29 Composiciones de vacuna.

Country Status (12)

Country Link
US (2) US6129922A (es)
EP (1) EP0714307B1 (es)
JP (1) JP3883203B2 (es)
KR (1) KR100341958B1 (es)
AT (1) ATE185073T1 (es)
AU (1) AU674983B2 (es)
DE (1) DE69420970T2 (es)
DK (1) DK0714307T3 (es)
ES (1) ES2139083T3 (es)
GB (1) GB9316745D0 (es)
GR (1) GR3032134T3 (es)
WO (1) WO1995005194A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
WO2000045847A1 (en) 1999-02-05 2000-08-10 Alk-Abelló A/S Novel mucosal delivery system
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
WO2003043574A2 (en) * 2001-11-19 2003-05-30 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
KR100748842B1 (ko) 2004-09-09 2007-08-13 주식회사한국야쿠르트 에이형 간염바이러스에 대한 항체 제조방법 및 그 응용

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69005572T2 (de) * 1989-09-08 1994-04-07 Takeda Chemical Industries Ltd Fusionsproteine und Herstellung davon.
JPH03135923A (ja) * 1989-10-20 1991-06-10 Chemo Sero Therapeut Res Inst 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5549896A (en) * 1991-05-08 1996-08-27 Schweiz. Serum- & Impfinstitut Bern Hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
DE19581492T1 (de) 1994-02-03 1997-06-19 Analogic Corp Röntgenstrahl-Tomographiesystem und Verfahren zur Verbesserung der Qualität eines abgetasteten Bildes
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same

Also Published As

Publication number Publication date
GB9316745D0 (en) 1993-09-29
AU7235694A (en) 1995-03-14
US6129922A (en) 2000-10-10
KR100341958B1 (ko) 2003-03-15
AU674983B2 (en) 1997-01-16
EP0714307B1 (en) 1999-09-29
GR3032134T3 (en) 2000-04-27
KR960703619A (ko) 1996-08-31
DE69420970D1 (de) 1999-11-04
DK0714307T3 (da) 2000-04-10
ATE185073T1 (de) 1999-10-15
WO1995005194A1 (en) 1995-02-23
EP0714307A1 (en) 1996-06-05
DE69420970T2 (de) 2000-03-30
JP3883203B2 (ja) 2007-02-21
US20030007979A1 (en) 2003-01-09
JPH09501437A (ja) 1997-02-10
US6699480B2 (en) 2004-03-02

Similar Documents

Publication Publication Date Title
ES2139083T3 (es) Composiciones de vacuna.
BRPI9911870B8 (pt) vacina de parvovírus e circovírus de suíno
DE3853210D1 (de) Verwendung eines viralen glykoprotein-impstoffes für intranasale immunisierung gegen eine virusinfektion.
AU2002254901A1 (en) Influenza vaccine formulations for intradermal delivery
DK1147117T3 (da) Immunologiske adjuvansforbindelser
CY1106635T1 (el) Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια
AR023535A1 (es) Nuevas composiciones.
DE59913046D1 (de) Influenzavirus-impfstoffzusammensetzung
ES2174839T3 (es) Oligosido derivado de un poliosido antigenico obtenido de un agente patogeno.
EP2066332A4 (en) FLUID MIXTURE OF MANNANE AND A GRIPPE ANTIGEN
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
ATE47524T1 (de) Hundeparvovirus-impfstoffe.
NO331017B1 (no) Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning.
Zhang et al. Construction and immunogenicity of DNA vaccines encoding fusion protein of murine complement C3d-p28 and GP5 gene of porcine reproductive and respiratory syndrome virus
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
WO2001082962A3 (en) Immunizing against hiv infection
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
CA2072982A1 (en) Hepatitis a vaccines
DK1442124T3 (da) Polypeptidantigen, der danner en mimetisk struktur af gp41-mellemstanden
DK284389D0 (da) Precursorantigener
ATE204761T1 (de) Pharmazeutische antigen-/antikörperpräparation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 714307

Country of ref document: ES